AKT1 and nasopharyngeal carcinoma: Mk-2206 is an inhibitor of Akt, which has limited activity in the heavily pre-treated group of patients in a multicenter phase II clinical trial.242 Further studies are needed to select appropriate Akt inhibitors to treat NPC.